Genitourinary Radiology: Page 66

Molecular Insight starts Trofex trial
By AuntMinnie.com staff writers
Molecular Insight Pharmaceuticals of Cambridge, MA, has begun a phase I clinical trial for its Trofex molecular imaging program for detecting and staging metastatic prostate cancer.
June 11, 2008
IBA, Wilex ink licensing pact
By AuntMinnie.com staff writers
Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.
June 5, 2008
Radiation therapy for prostate cancer linked to secondary cancers
By Cynthia E. Keen
Patients undergoing external-beam radiation therapy (EBRT) for localized prostate cancer may be at an increased risk for secondary malignancies 10 or more years after initial treatment. French-Canadian men who received EBRT between 1983 and 2004 were found to have a higher prevalence of bladder, rectal, and lung cancers compared to those who had a radical prostatectomy.
May 27, 2008
Ultrasound contrast boosts prostate biopsy yield
By Erik L. Ridley
ATLANTIC CITY, NJ - Prostate biopsy guided by contrast-enhanced color Doppler ultrasound is superior to systematic biopsy in a screening setting, according to research presented at the Leading Edge in Diagnostic Ultrasound conference this week.
May 21, 2008
Clinically significant contrast-induced nephropathy rare
By Eric Barnes
LAS VEGAS - Retrospective studies have shown that contrast-induced nephropathy (CIN) following CT occurs in about 1% to 12% of patients undergoing contrast-enhanced CT. These studies also demonstrate an association between CIN and mortality. However, a new prospective study presented at the 2008 International Symposium on Multidetector-Row CT found that contrast-enhanced CT can be safely performed in most patients with chronic kidney disease.
May 13, 2008
IsoRay posts sales increase, net loss in Q3
By AuntMinnie.com staff writers
More orders for its Proxcelan cesium-131 brachytherapy seeds to treat prostate cancer helped increase sales for IsoRay of Richland, WA, in the company's third quarter of fiscal 2008.
May 13, 2008
CT planning eliminates need for urethrography in prostate
By Brian Casey
Radiation therapy planning based on 3D CT has revolutionized radiation oncology, and researchers from the University of Texas Health Science Center believe they've found another benefit: the elimination of retrograde urethrography when planning treatment for prostate cancer. Their study results were published in the May 1 issue of the International Journal of Radiation Oncology, Biology, Physics.
May 11, 2008
ProstaScint sales boost Cytogen's Q1
By AuntMinnie.com staff writers
Biopharmaceutical firm Cytogen enjoyed growth in revenue for its first quarter of 2008, the company reported.
May 7, 2008
Eigen nets clearance for Artemis
By AuntMinnie.com staff writers
Medical imaging developer Eigen has received U.S. Food and Drug Administration (FDA) clearance for its ei-Nav/Artemis prostate cancer imaging device.
May 6, 2008
Ultrasound scan protocols for nonmedical personnel offer value
By Erik L. Ridley
Training nonmedical personnel to perform simple volume ultrasound scan protocols can produce effective results, according to researchers from the University of Vermont School of Medicine. They developed four protocols to scan the thyroid, gallbladder, kidney, and female transabdominal pelvis. To test the protocols, they had volunteers without imaging experience undergo a 20- to 30-minute training session for each protocol.
April 28, 2008
Aloka rolls out ProSound 3500SX in U.S.
By AuntMinnie.com staff writers
Ultrasound vendor Aloka will release its ProSound 3500SX ultrasound system at the 2008 American College of Obstetricians and Gynecologists (ACOG) meeting next week in New Orleans.
April 27, 2008
Contrast agent osmolality makes no difference in PCI of renal disease patients
By Edward Susman
The type of contrast medium used in percutaneous coronary interventions (PCIs) makes no statistically significant difference in outcomes among chronic renal disease patients in terms of nephrotoxicity, according to a study by researchers from Germany. They presented their findings at the recent 2008 American College of Cardiology (ACC) meeting in Chicago.
April 16, 2008
Previous Page
Page 66 of 93
Next Page